New AI Tool Accelerates Disease Treatments

University of Virginia School of Medicine scientists have created a computational tool to accelerate the development of new disease treatments. The tool goes beyond current artificial intelligence (AI) approaches by identifying not just which patient populations may benefit but also how the drugs work inside cells.

The researchers have demonstrated the tool's potential by identifying a promising candidate to prevent heart failure, a leading cause of death in the United States and around the world.

The new AI tool called LogiRx, can predict how drugs will affect biological processes in the body, helping scientists understand the effects the drugs will have other than their original purpose. For example, the researchers found that the antidepressant escitalopram, sold as Lexapro, may prevent harmful changes in the heart that lead to heart failure, a condition that causes almost half of all cardiovascular deaths in the United States.

"AI needs to move from detecting patterns to generating understanding," said UVA's Jeffrey J. Saucerman. PhD. "Our LogiRx tool helps us identify not just which drugs can be repurposed for heart disease but how they work in the heart."

Heart failure kills more than 400,000 Americans every year. One of its hallmarks is the overgrowth of cells that thicken the heart muscle and prevent the organ from pumping blood as it should. This is known as cardiac hypertrophy.

Saucerman and his team, led by PhD student Taylor Eggertsen, wanted to see if LogiRx could identify drugs with the potential to prevent cardiac hypertrophy and, ultimately, head off heart failure. They used the tool to evaluate 62 drugs that had been previously identified as promising candidates for the task. LogiRx was able to predict "off-target" effects for seven of these drugs that could help prevent harmful cellular hypertrophy, which were confirmed in cells for two of the drugs.

The scientists then evaluated LogiRx’s predictions by doing lab tests and by looking at outcomes in patients taking the drugs. The latter revealed that patients taking escitalopram were significantly less likely to develop cardiac hypertrophy.

"LogiRx identifies unexpected new uses for old drugs that are already shown to be safe in humans," said Eggertsen, in UVA's Department of Biomedical Engineering, a joint program of the School of Medicine and School of Engineering. "This tool can help researchers explore new patient populations that could benefit from a drug or to avoid unwanted side effects."

Additional lab research and clinical trials will be needed before doctors might start prescribing escitalopram for heart health. But Saucerman is excited about the potential of LogiRx for advancing and accelerating new treatments not just for cardiac hypertrophy but for a host of other serious medical conditions.

"AI is accelerating many aspects of drug development, but it has made less progress in providing the required understanding of how these drug work in the body," Saucerman said. "LogiRx is a step towards combining AI with existing knowledge of how cells work to find new uses for old drugs."

Eggertsen TG, Travers JG, Hardy EJ, Wolf MJ, McKinsey TA, Saucerman JJ.
Logic-based machine learning predicts how escitalopram attenuates cardiomyocyte hypertrophy.
Proc Natl Acad Sci U S A. 2025 Mar 11;122(10):e2420499122. doi: 10.1073/pnas.2420499122

Most Popular Now

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Northern Ireland Completes Nationwide Ro…

Go-lives at Western and Southern health and social care trusts mean every pathology service is using the same laboratory information management system; improving efficiency and quality. An ambitious technology project to...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

Groundbreaking TACIT Algorithm Offers Ne…

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment...

The Many Ways that AI Enters Rheumatolog…

High-resolution computed tomography (HRCT) is the standard to diagnose and assess progression in interstitial lung disease (ILD), a key feature in systemic sclerosis (SSc). But AI-assisted interpretation has the potential...